#Rc quickcal full#
#Rc quickcal Bluetooth#

The recently FDA-approved human anti-CD20 mAb ofatumumab (OFA) has appreciable activity in the treatment of CLL and could be an important additional drug in combination therapy. Rituximab (RTX, specific for CD20) based chemoimmunotherapy has markedly increased response rates in the treatment of CLL and addition of RTX to fludarabine and cyclophosphamide increases overall survival after initial treatment of progressive CLL. The CD52 specific mAb alemtuzumab (ALM) is highly effective in the treatment of CLL and is especially important in the management of patients with TP53 defective or purine analogue refractory disease. Monoclonal antibodies (mAb) that target certain proteins on B cells are valuable drugs for the treatment of chronic lymphocytic leukemia (CLL). Improvement of clinical responses will require determining the mechanisms of CDC resistance and developing methods to overcome this problem.

Approximately 10% of CLL cells were resistant to CDC because of lower levels of complement activation or decreased cytotoxicity of activated complement. OFA significantly increased complement activation and CDC in ALM-treated CLL cells suggesting that combining ALM and OFA could improve clinical outcome in patients with CLL. The subpopulation of CDC resistant CLL cells was examined for levels of C3b and C5b-9 binding, and expression of complement regulatory proteins. CLL cells from 21 previously untreated patients with progressive disease were tested in vitro for mAb binding, complement activation, and CDC.

We hypothesized that alemtuzumab (ALM) mediated CDC would be increased by addition of ofatumumab (OFA). This is the first time that a crystal-free radio is participating in a channel-hopping enabled TSCH network.Complement dependent cytotoxicity (CDC) is an important mechanism of action for monoclonal antibodies (mAb) used in the treatment of chronic lymphocytic leukemia (CLL).

#Rc quickcal full#

Finally, we demonstrate a heterogeneous network-composed of a SCµM chip and an OpenMote device-implementing a full 6TiSCH Industrial IoT protocol stack, which uses time synchronization and channel hopping. We further validate that, once it has self-calibrated, a SCµM chip can reliably communicate with off-the-shelf IEEE802.15.4 devices. We show that a SCµM chip can self-calibrate against this QuickCal Box in fewer than 3 min. This article introduces QuickCal, a solution that allows a SCµM chip to self-calibrate against off-the-shelf devices dedicated to assisting with its calibration.

This is a challenge since its on-board RC and LC-based resonating circuits have a drift rate that can be 3 orders of magnitude worse than crystal-based oscillators typically used in today's radios. However, before it can be part of such networks, the crystal-free SCµM chip needs to be able to accurately tune its communication frequency to synchronize to the network.

#Rc quickcal Bluetooth#

Abstract : The Single Chip Micro Mote (SCµM) is a crystal-free single-chip mote that brings us one step closer to the Smart Dust vision, in particular as it can communicate with off-the-shelf IEEE802.15.4 and Bluetooth Low Energy devices.